CentralCharts: Supercharge your portfolio with groundbreaking tools.

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitions Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced...

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to...

Pangaea Logistics Solutions Ltd. Reports Financial Results for the Quarter Ended March 31, 2024 PR Newswire NEWPORT, R.I., May 9, 2024 NEWPORT, R.I. , May 9, 2024 /PRNewswire/ -- Pangaea Logistics Solutions Ltd. ("Pangaea" or the "Company") (Nasdaq: PANL), a global provider of comprehensive maritime logistics solutions, announced today its results for the three months ended March 31, 2024. FIRST QUARTER 2024 RESULTS Net income attributable to Pangaea of $11.7 million , or $0.25 per diluted share...

Dogness Announces Entry into US$5.0 Million Private Placement PR Newswire PLANO, Texas, May 9, 2024 PLANO, Texas , May 9, 2024 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that it entered into a private placement transaction (the "Private Placement") for US$5.0 million in gross proceeds, from the sale of 2,000,000 of the...

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC ® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early...

Strong contribution from Performance Chemicals drives operating income growth of 23 percent $80.6 million cash generated from operations; Net cash improves to $270.1 million Dividend increased by 10 percent; Strong debt-free balance sheet GAAP EPS of $1.65 and adjusted non-GAAP EPS of $1.75 ENGLEWOOD, Colo., May 09, 2024 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the first quarter ended March 31, 2024. The Company declared its semi-annual dividend...